A risk-defraying pact between Amgen Inc. and Novartis AG will align the companies' early stage efforts to fight Alzheimer's disease (AD) behind Novartis' phase I/II oral beta-site APP-cleaving enzyme-1 (BACE) inhibitor, CNP-520, while also enlisting Novartis as a co-developer and eventual co-seller of Amgen's two migraine candidates in markets beyond North America and Japan.